Annual report pursuant to Section 13 and 15(d)

Stock-based Compensation (Details Narrative)

v3.22.1
Stock-based Compensation (Details Narrative) - USD ($)
12 Months Ended
Nov. 01, 2021
Oct. 06, 2021
Sep. 01, 2021
Aug. 05, 2021
Jul. 01, 2021
Jun. 08, 2021
Feb. 24, 2021
Feb. 16, 2021
Oct. 06, 2020
Dec. 31, 2021
Dec. 31, 2020
Jan. 26, 2021
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount                   $ 2,430,142      
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition                   1 year 8 months 12 days      
Restricted stock unit shares for future issuance                   39,786      
Number of shares, granted                   17,800      
Accrued expenses                   $ 279,265 $ 224,676    
Options grant in period                   30,000      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value                   $ 1,659,909 $ 1,221,952    
Options, exercised                   0 0    
Fair value of warrants                   $ 391,108      
Private Placement [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Warrants issued               79,268          
Shares issued during period, shares             1,321,132            
Placement Agent [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Shares issued during period, shares               1,321,132          
Restricted Stock [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Number of shares, granted                   37,500 336,860    
Number of shares vested   12,500   55,143           281,721      
Number of shares, forfeited                   10,706 23,804    
Number of restricted stock shares outstanding                   91,109 122,782  
Number of stock vested and issued                   58,467 190,274    
Restricted Stock [Member] | Employment Termination [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Number of shares, forfeited                   1,530      
Restricted Stock [Member] | Federal, State and Local [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Number of shares, forfeited                   9,176 23,804    
Restricted Stock [Member] | Underwritten Public Offering [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Number of shares vested                 214,078        
Restricted Stock Units (RSUs) [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Number of shares, granted                   457,593      
Number of shares vested                   14,000      
Number of shares, forfeited                   4,000      
Number of restricted stock shares outstanding                   249,100      
Stock Option [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value                   $ 5.23      
Directors [Member] | Restricted Stock [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Number of shares, granted                   17,572      
Accrued expenses                   $ 120,000      
Employees [Member] | Restricted Stock [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Number of shares, granted           37,500              
Employees [Member] | Restricted Stock Units (RSUs) [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Number of shares, granted         202,930         144,457      
Number of shares vested 39,786                        
Number of shares, forfeited         4,000                
Number of restricted stock shares outstanding         198,930                
Employees [Member] | Restricted Stock Units (RSUs) [Member] | Service condition [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Number of shares, granted         79,572                
Vesting period description         39,786 shares of common stock vest on July 1, 2022 and the remaining vest on July 1, 2023                
Employee and Consultant [Member] | Restricted Stock Units (RSUs) [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Number of shares, granted                   110,206      
Number of shares vested                   6,250      
Number of stock vested and issued                   14,000      
Employee [Member] | Restricted Stock Units (RSUs) [Member] | Performance condition [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Number of shares, granted         119,358                
Terms of vesting         119,358 shares of common stock vest upon meeting the following performance criteria: (i) RSUs for the future issuance of 39,786 shares of common stock vest upon the completion of the interim analysis of Cohorts 1 and 2 for our PCS6422 Phase 1B clinical trial; (ii) RSUs for the future issuance of 39,786 shares of common stock vest upon the completion of the interim analysis of our PCS499 Phase 2B clinical trial; and (iii) RSUs for the future issuance of 39,786 shares of common stock vest upon the next capital raise(s) totaling a cumulative amount of at least $30 million.                
Consultant [Member] | Warrant [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Warrants issued     50,000                 100,000  
Warrant expiration date     Sep. 01, 2024                 Jan. 11, 2023  
Class of Warrant or Right, Exercise Price of Warrants or Rights     $ 8.00                 $ 7.18  
Warrants, grant date fair value     $ 139,900                 $ 321,158  
Consultant [Member] | Warrant [Member] | September 30, 2021 [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Number of warrant vested     12,500                    
Consultant [Member] | Warrant [Member] | December 31, 2021 [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Number of warrant vested     12,500                    
Consultant [Member] | Warrant [Member] | March 31, 2022 [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Number of warrant vested     12,500                    
Consultant [Member] | Warrant [Member] | June 30, 2022 [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Number of warrant vested     12,500                    
Placement Agent [Member] | Private Placement [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Warrants issued               79,268          
Warrant expiration date               Feb. 16, 2023          
Class of Warrant or Right, Exercise Price of Warrants or Rights               $ 9.30          
2019 Plan [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Maximum equity available for issuance under the plan                   3,000,000      
Shares available for future grants                   1,899,696      
2019 Plan [Member] | Employees and Directors [Member] | Restricted Stock [Member]                          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                          
Number of shares, granted                   37,500 336,860